Sarepta Therapeutics (NASDAQ:SRPT) Issues Quarterly Earnings Results

Sarepta Therapeutics (NASDAQ:SRPT) posted its earnings results on Thursday. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.06, FiscalAI reports. The company had revenue of $381.35 million during the quarter, compared to analyst estimates of $352.20 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%. Sarepta Therapeutics’s revenue was down 4.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.13) earnings per share.

Here are the key takeaways from Sarepta Therapeutics’ conference call:

• Sarepta raised the low end of its 2026 net product revenue guidance by $50 million to $1.25 billion–$1.3 billion, citing strong PMO sales and stabilization in ELEVIDYS. Q3 product revenue was $324 million, down 13% year over year; ELEVIDYS contributed $83 million and the PMO franchise $240 million.
• ELEVIDYS enrollment-form activity was in line with Q2, which management described as a new baseline; the company expects Q4 ELEVIDYS revenue to be roughly in line with Q3. Executives said long-term data and results in patients ages 8–12 are supporting physician and family discussions, but offered no timing for renewed growth.
• Sarepta reported $23 million in Q3 non-GAAP operating profit and nearly $1 billion in cash and investments; management said its base business generated nearly $300 million of cash year to date after adjusting for Arrowhead collaboration payments. The company also narrowed its full-year non-GAAP R&D and SG&A expense guidance to $800 million–$825 million.
• Q3 product-revenue gross margin was 59%, including a $52 million take-or-pay charge for unmanufactured ELEVIDYS inventory that reduced the quarter’s margin by about 19 percentage points. Sarepta also said it expects competition for its exon 51 therapy in early 2027, though it does not expect widespread switching of stable patients initially.
• Data from the DM1 and FSHD multiple-ascending-dose studies are expected in the coming weeks and are intended to guide dose selection and pivotal-trial plans; those programs have not yet demonstrated clinical benefit in these studies. Sarepta will not resume the ENVISION trial, citing practical barriers, and is relying on ENDEAVOR Cohort 8 data to inform discussions with the FDA about ELEVIDYS in non-ambulatory patients.

Sarepta Therapeutics Trading Up 1.4%

NASDAQ:SRPT traded up $0.25 on Friday, reaching $17.82. The company’s stock had a trading volume of 2,596,194 shares, compared to its average volume of 2,726,443. Sarepta Therapeutics has a 12-month low of $14.68 and a 12-month high of $24.68. The stock has a 50 day moving average price of $19.20 and a 200 day moving average price of $18.66. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SRPT. Benchmark reissued a “sell” rating on shares of Sarepta Therapeutics in a report on Wednesday, September 9th. William Blair upgraded Sarepta Therapeutics to a “hold” rating in a research report on Wednesday, September 23rd. Zacks Research cut Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. HC Wainwright reissued a “sell” rating and issued a $5.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 5th. Finally, Weiss Ratings cut shares of Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 28th. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and seven have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $23.40.

Trending Headlines about Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada raised its price target from $17 to $18, while maintaining a “sector perform” rating. Sarepta reported Q3 EPS of $0.13, above the $0.07 consensus cited by MarketBeat, and revenue of $381.35 million versus its $352.20 million estimate. MarketBeat earnings report
• Neutral Sentiment: Baird lowered its price target to $18. The target is close to the $17.82 share price cited in the report, suggesting limited upside at that level. StreetInsider report
• Negative Sentiment: Other earnings coverage said SRPT’s $0.13 EPS missed the Zacks consensus estimate of $0.37. Revenue was down 4.5% year over year, and reports said weaker Elevidys sales weighed on investor sentiment. Published earnings benchmarks differ, so the quarter’s result depends on which estimate is used. Zacks earnings coverage
• Negative Sentiment: A Sarepta-Hansa gene-therapy study has ended, raising questions for investors about the collaboration and its development prospects. The available report summary does not specify the study’s results or implications. TipRanks report

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.